Valerie Holmes
Psychiatry · Durham, NCNPI 1871602532
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Alfasigma USA, Inc. at 44.6% of the total. Reporting peaked in 2021 at $6,447 and has fallen 89.6% since, to $670 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $126.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alfasigma USA, Inc.$8K
- Neurocrine Biosciences, Inc.$4K
- AbbVie$3K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Sunovion Pharmaceuticals Inc.$221
- Johnson & Johnson$187
- plus $875 from 10 others
What the payments were for
- Consulting fees$7,89945%
- Speaking & faculty fees$2,60015%
- Travel & lodging$730%
- Food & beverage$7,12240%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alfasigma USA, Inc. | 3 | $7,899 |
| Neurocrine Biosciences, Inc. | 47 | $3,862 |
| AbbVie(2 entities) | 10 | $2,751 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | $1,915 |
| Sunovion Pharmaceuticals Inc. | 8 | $221 |
| Johnson & Johnson | 5 | $187 |
| Otsuka America Pharmaceutical, Inc. | 10 | $177 |
| Alkermes, Inc. | 7 | $159 |
| Teva Pharmaceuticals USA, Inc. | 4 | $148 |
| Lundbeck LLC | 5 | $102 |
| Indivior Inc. | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Avanir Pharmaceuticals, Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Shire North American Group Inc | 1 | $15 |
| Orexo US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,400
- INGREZZA$1,802
- REXULTI$866
- VIIBRYD$200
- INVEGA SUSTENNA$128
- INVEGA TRINZA$128
- LATUDA$119
- AUSTEDO$114
How this compares
$17,710 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 17 | $79 |
| Sertraline Hcl | 14 | $42 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Durham
- Mark ReynoldsDurham$3.2M
- Steven SzaboDurham$360K
- Andrew KrystalDurham$234K
- Ranjan SudanDurham$81K
- Caleb WhitenackDurham$68K
- Paolo MannelliDurham$38K
- P DoraiswamyDurham$35K
- David JarrettDurham$28K
- Steven PrakkenDurham$22K
- Mustafa HusainDurham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.